Stockscreener 앱 받기
0.3021
3.46%
0.0101
시간 외 거래:
.30
-0.0021
-0.70%
전일 마감가:
$0.292
열려 있는:
$0.2912
하루 거래량:
809.34K
Relative Volume:
0.47
시가총액:
$13.46M
수익:
-
순이익/손실:
$-37.75M
주가수익비율:
-0.093
EPS:
-3.25
순현금흐름:
$-30.91M
1주 성능:
-16.96%
1개월 성능:
+4.35%
6개월 성능:
-86.01%
1년 성능:
-92.43%
1일 변동 폭
$0.2912
$0.3149
1주일 범위
$0.2899
$0.38
52주 변동 폭
$0.224
$4.1499
Cellectar Biosciences Inc Stock (CLRB) Company Profile
명칭
Cellectar Biosciences Inc
전화
(608) 441-8120
주소
100 CAMPUS DRIVE, FLORHAM PARK, NJ
CLRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
0.3021 | 13.46M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-05 | 재개 | Ladenburg Thalmann | Buy |
| 2020-07-01 | 개시 | Oppenheimer | Outperform |
| 2020-01-21 | 재개 | ROTH Capital | Buy |
| 2019-09-13 | 개시 | ROTH Capital | Buy |
| 2016-12-21 | 개시 | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc 주식(CLRB)의 최신 뉴스
Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Cellectar Biosciences (CLRB) to Release Earnings on Wednesday - Defense World
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
StockNews.com Begins Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences Enhances CEO and COO Severance Benefits - TipRanks
What is Roth Capital’s Estimate for CLRB FY2029 Earnings? - Defense World
Earnings call transcript: Cellectar Biosciences Q4 2024 sees restructuring amid losses - Investing.com Australia
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call Transcript - Insider Monkey
Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlight - GuruFocus.com
Cellectar Biosciences Faces Financial and Legal Turmoil Amidst Restated Earnings - TipRanks
Cellectar Biosciences Advances Cancer Drug Pipeline - TipRanks
Cellectar Biosciences Earnings Call: Mixed Outlook Amid Successes and Challenges - TipRanks
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update - GlobeNewswire
Cellectar's Breakthrough: 83.6% Response Rate Puts FDA Fast Track Within Reach - StockTitan
Cellectar Biosciences Provides Update on FDA Regulatory Path for Iopofosine I 131 in Waldenström Macroglobulinemia and Advances Phase 1 Trials for New Radioconjugates - Nasdaq
Cellectar Biosciences COO acquires $8,400 in stock By Investing.com - Investing.com Canada
Cellectar Biosciences COO acquires $8,400 in stock - Investing.com India
Cellectar Biosciences to Present at the 37th Annual Roth Conference - Quantisnow
Cellectar Biosciences Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Cellectar Biosciences, Inc. to Present at 37th Annual Roth Conference - Nasdaq
Cancer Treatment Breakthrough? Cellectar Biosciences Reveals Latest Progress at Major Investor Conference - StockTitan
Before You Invest, Make Sure You Check This Cellectar Biosciences Inc (NASDAQ: CLRB) Analysis - stocksregister.com
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com - Defense World
Cellectar Biosciences (CLRB) Expected to Announce Quarterly Earnings on Thursday - Defense World
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025 - GlobeNewswire
Cellectar Biosciences, Inc. to Report 2024 Financial Results and Corporate Update on March 13, 2025 - Nasdaq
When Will Cellectar Biosciences Reveal Its 2024 Financial Performance? - StockTitan
StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated at StockNews.com - Defense World
CLRB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Prepare Yourself for Liftoff: Cellectar Biosciences Inc (CLRB) - SETE News
SEC Form 424B3 filed by Cellectar Biosciences Inc. - Quantisnow
A look into Cellectar Biosciences Inc (CLRB)’s deeper side - SETE News
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Cellectar Biosciences, Inc. to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 - Nasdaq
Cellectar Biosciences Showcases Cancer Treatment Pipeline at Major Healthcare Conference - StockTitan
Examining Cellectar Biosciences Inc (CLRB) stock is warranted - US Post News
Cellectar faces Nasdaq delisting over share price rule - MSN
Market Momentum Report: Cellectar Biosciences Inc (CLRB)’s Positive Close at 0.26 - The Dwinnex
Rosalind Advisors, Inc. Increases Stake in Cellectar Biosciences Inc - GuruFocus.com
Cellectar Biosciences Inc (CLRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):